BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 24131801)

  • 1. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.
    Potkin SG; Bera R; Eramo A; Lau G
    Clin Schizophr Relat Psychoses; 2017; 10(4):211-221. PubMed ID: 24846880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.
    Weiden PJ; Roma RS; Velligan DI; Alphs L; DiChiara M; Davidson B
    J Clin Psychiatry; 2015 Jun; 76(6):684-90. PubMed ID: 25939027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics.
    Robinson DG; Subramaniam A; Fearis PJ; Shi R; Walsh M; Hanna LA; Kane JM
    Psychiatr Serv; 2020 Apr; 71(4):337-342. PubMed ID: 31847736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients.
    Kim SW; Lee YH; Jang JE; Yoo T; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2013 Mar; 28(2):80-6. PubMed ID: 23325306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
    Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
    Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics: An Online Survey Study From India.
    Grover S; Sahoo S; Mehra A
    J Clin Psychopharmacol; 2019; 39(6):611-619. PubMed ID: 31688382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.
    Geerts P; Martinez G; Schreiner A
    BMC Psychiatry; 2013 Feb; 13():58. PubMed ID: 23414331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
    Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
    J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
    Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
    J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.